Clinical Trial: Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Open, Noncomparative Trial of Multidrug Regimens Containing Azithromycin and Rifabutin Administered Three Times Per Week for the Treatment of M. Avium Complex (MAC) Lung D

Brief Summary: To determine the safety and efficacy of azithromycin, rifabutin and ethambutol given three times weekly in the treatment of lung infection with M. avium complex(MAC)

Detailed Summary: Azithromycin given 3 times weekly along with rifampin/rifabutin and ethambutol for treatment of MAC
Sponsor: The University of Texas Health Science Center at Tyler

Current Primary Outcome: Clinical and microbiological outcomes such as clinical symptoms and laboratory cultures [ Time Frame: Monthly while on treatment, then followup after therapy discontinuation will be at one month, then at three months, then at six months, then annually and prn for life ]

Original Primary Outcome: Clinical and microbiological outcomes such as clinical symptoms and laboratory cultures [ Time Frame: Monthly while on treatment, then followup after therapy discontinuation will be at one month, then at three months, then at six months, then annually and prn for life ]

Current Secondary Outcome: Microbiological cultures [ Time Frame: Monthly while on treatment, then followup after therapy discontinuation will be at one month, then at three months, then at six months, then annually and prn for life ]

Original Secondary Outcome: Microbiological cultures [ Time Frame: Monthly while on treatment, then followup after therapy discontinuation will be at one month, then at three months, then at six months, then annually and prn for life ]

Information By: The University of Texas Health Science Center at Tyler

Dates:
Date Received: January 11, 2008
Date Started: December 1994
Date Completion:
Last Updated: May 18, 2017
Last Verified: May 2017